News and Events
September 21, 2023 Press
Precision therapeutics: optimizing early discovery
Precision medicine tailors therapeutics to individual patients’ diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.
Precision therapeutics: optimizing early discovery Read moreJuly 28, 2023 Press
Where the medicine of the future is already being lived in the present
More than 20 years ago, Indivumed set out to create a solid database for the individualized cancer therapy of the future. Today, founder and CEO Prof. Dr. Hartmut Juhl considers himself to have made considerable progress along this path, not least thanks to his company's unique database. In an interview with Wirtschaftsforum, the passionate entrepreneur talked about the future prospects.
Where the medicine of the future is already being lived in the present Read moreJuly 24, 2023 Press
Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach
Read our at MDPI newly published paper on "Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach".
Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach Read moreJune 06, 2023 Press
Optimizing early discovery within precision therapeutics
Precision medicine involves tailoring a therapeutic to a patients’ disease. Here, we delve into the critical role played by the quality of the samples, the data, and the analysis in the development of these targeted therapies. Read the full article.
Optimizing early discovery within precision therapeutics Read more
RESEARCH PUBLICATIONS & Posters
Video
Indivumed Therapeutics:
Data-driven precision oncology
Introducing:
Indivumed Therapeutics, April 2023
In Focus:
The Future of Indivumed – Interview with Prof. Dr. Hartmut Juhl, Indivumed Therapeutics
In Focus:
Therapeutic target Identification – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
Clinical Network – Interview with Dr. Susanne Arbogast, Indivumed Therapeutics
In Focus:
nRavel – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
Data Depth – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
Data Quality – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
Our Vision – Interview with Dr. Jonathan Woodsmith, Indivumed Therapeutics
In Focus:
AI – Interview with John L. Marshall, MD, Georgetown University Hospital
In Focus:
Precision Oncology – Interview with John L. Marshall, MD, Georgetown University Hospital